Longevity Health Holdings, Inc. is a regenerative medicine biotech company, which focuses on leveraging its core platform technology plasma based bioactive material to stimulate tissue repair or growth after severe injury, disease or aging. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 15 full-time employees. The company went IPO on 2021-07-29. The firm has two cosmetic product lines, Carmell Secretomeand and Elevai Exosomes, that support skin and hair health. All of its cosmetic skincare and haircare products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. The Carmell Secretome consists of a potent cocktail of growth factors, proteins, and peptides extracted from allogeneic human platelets. The Carmell Secretome product portfolio and pipeline includes Face and Neck Collection (Retail), ProSynergy Collection (Doctors/Medspas), and others. The Elevai Exosomes are nano-sized extracellular vesicles containing growth factors, cytokines, peptides, and other small molecules involved in the body’s natural healing process. The Elevai Exosomes skincare products include Elevai Empower and Elevai Enfinity.
根據最新的財務報表(Form-10K),Longevity Health Holdings Inc 的總資產為 $0,淨損失為 $0
XAGE 的關鍵財務比率是什麼?
Longevity Health Holdings Inc 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Longevity Health Holdings Inc 的收入按細分市場或地理位置如何劃分?
Longevity Health Holdings Inc 最大收入來源為 Residential Small and Medium Business - Incumbent Broadband Markets,在最近的收益報告中收入為 177,485,000。就地區而言,United States 是 Longevity Health Holdings Inc 的主要市場,收入為 328,058,000。
Longevity Health Holdings Inc 是否盈利?
無,根據最新的財務報表,Longevity Health Holdings Inc 的淨損失為 $0